The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico

References

• Coleman R. Bisphosphonates: clinical experience. Oncologist. 2004;9(Suppl_4):14–27.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res. 2005;11(14):5223–5232.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Hameed A, Brady JJ, Dowling P, et al. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014;7:33–42.
   PubMedGoogle Scholar
• Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082–1090.
   PubMed Web of Science ®Google Scholar
• Silbermann R, Roodman G. Hematologic malignancies and bone. In: Rosen C, editor. Primer on the multiple myeloma-related complications. 8th ed. Ames (IA): Wiley-Blackwell; 2013.
   Google Scholar
• Fallowfield L, Cleeland C, Von Moos R. Pain progression and analgesic use after skeletal-related events in patients with solid tumors and bone metastases. Support Care Cancer 2016;24:1327–1337.
   PubMed Web of Science ®Google Scholar
• Norgaard M, Jensen AO, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–167.
   PubMed Web of Science ®Google Scholar
• Yong M, Jensen AO, Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat. 2011;129(2):495–503.
   PubMed Web of Science ®Google Scholar
• Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249–264.
   PubMed Web of Science ®Google Scholar
• Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–iii137.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Delea TE, Cong Z, et al. Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer. 2014;22(1):103–113.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–2621.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, Double-Blind study. Lancet. 2011;377(9768):813–822.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–1132.
   PubMed Web of Science ®Google Scholar
• Al Farii H, Frazer A, Farahdel L, et al. Bisphosphonates versus denosumab for prevention of pathological fracture in advanced cancers with bone metastasis: a meta-analysis of randomized controlled trials. J Am Acad Orthop Surg Glob Res Rev. 2020;4(8):e2000045.
   Google Scholar
• Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679–687.
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341–347.
   PubMedGoogle Scholar
• Hoefeler H, Duran I, Hechmati G, et al. Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective – prospective observational study – a cohort from 4 European countries. J Bone Oncol. 2014;3(2):40–48.
   PubMed Web of Science ®Google Scholar
• Hechmati G, Cure S, Gouepo A, et al. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16(5):691–700.
   PubMedGoogle Scholar
• Lothgren M, Ribnicsek E, Schmidt L, et al. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm. 2013;20(4):227–231.
   PubMedGoogle Scholar
• Bhowmik D, Hines DM, Intorcia M, et al. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. J Med Econ. 2018;21(6):622–628.
   Google Scholar
• Biermann WA, Cantor RI, Fellin FM, et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone. 1991;12(Suppl 1):S37–S42.
   PubMed Web of Science ®Google Scholar
• Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301–308.
   PubMed Web of Science ®Google Scholar
• Broder MS, Gutierrez B, Cherepanov D, et al. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015;23(1):237–247.
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010;16(9):693–702.
   PubMed Web of Science ®Google Scholar
• McDougall JA, Bansal A, Goulart BH, et al. The clinical and economic impacts of Skeletal-Related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21(3):320–326.
   PubMed Web of Science ®Google Scholar
• Qian Y, Song X, Zhang K, et al. Short-term disability in solid tumor patients with bone metastases and skeletal-related events. J Med Econ. 2015;18(3):210–218.
   PubMed Web of Science ®Google Scholar
• Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109(11):2334–2342.
   PubMed Web of Science ®Google Scholar
• Felix J, Andreozzi V, Soares M, et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese national health system. Value Health. 2011;14(4):499–505.
   PubMed Web of Science ®Google Scholar
• Luftner D, Lorusso V, Duran I, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. SpringerPlus. 2014;3:328.
   PubMed Web of Science ®Google Scholar
• Pereira J, Body JJ, Gunther O, et al. Cost of skeletal complications from bone metastases in six European countries. J Med Econ. 2016;19(6):611–618.
   PubMed Web of Science ®Google Scholar
• McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–46.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Grey matters: a practical tool for searching health-related grey literature; 2018 [updated 2015]. Available from: https://www.cadth.ca/resources/finding-evidence/grey-matters
   Google Scholar
• Bank of America. Foreign exchange rates for U.S. Dollars; 2020. Available from: https://www.bankofamerica.com/foreign-exchange/exchange-rates.go
   Google Scholar
• Central Bank of Argentina. Central Bank of Argentina; 2020. Available from: http://www.bcra.gov.ar/
   Google Scholar
• Cristino J, Finek J, Maniadakis N, et al. The clinical and economic burden of skeletal related events in Austria, Czech Republic, Germany, Greece, Italy, Spain and Switzerland: a comparison between the use of denosumab and zoledronic acid in patients with prostate cancer and bone metastases. Value Health. 2015;18(7):A483.
   Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. GBD compare: University of Washington; 2017 [cited 2020 Feb]. Available from: https://vizhub.healthdata.org/gbd-compare/
   Google Scholar
• Cristino J, Finek J, Jandova P, et al. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. J Med Econ. 2017;20(8):799–812.
   PubMed Web of Science ®Google Scholar
• Stopeck A, Brufsky A, Kennedy L, et al. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020;23(1):37–47.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Cancer Observatory (Globocan) [cited 2020 Feb 15]. Available from: https://gco.iarc.fr/today/home
   Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program [cited 2020 Feb 15]. Available from: https://seer.cancer.gov/
   Google Scholar
• The World Bank Group. DataBank; 2020. Available from: https://databank.worldbank.org/home.aspx
   Google Scholar
• Hungria VTM, Lee JH, Maiolino A, et al. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol. 2019;98(4):941–949.
   PubMed Web of Science ®Google Scholar
• Amgen (Argentina) BdASRL. Local Market Research; 2020.
   Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–381.
   PubMed Web of Science ®Google Scholar
• Macherey S, Monsef I, Jahn F, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2017;12:CD006250.
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Kumar A, Miladinovic B, et al. Bisphosphonates in multiple myeloma: an updated network Meta-analysis. Cochrane Database Syst Rev. 2017;12:CD003188.
   PubMed Web of Science ®Google Scholar
• O'Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.
   PubMed Web of Science ®Google Scholar
• Pérez M, Garcia Perlaza J, Fletscher P, et al. Economic burden associated with Skeletal-Related events in patients with bone metastases in Colombia. Value Health. 2017;20(9):A423.
   Web of Science ®Google Scholar
• University College London. CCEMG – EPPI-Centre Cost Converter v.1.4; 2020. Available from: https://eppi.ioe.ac.uk/costconversion/
   Google Scholar
• Tanaka S, Suri G, Arancibia A, et al. Impacto econômico da adoção de denosumabe em pacientes com metástases ósseas ou mieloma múltiplo sob a perspectiva do sistema de saúde privado brasileiro. J Bras Econ Saúde (Impr). 2020;12(1):16–22.
   Google Scholar
• IMSS. GRD – IMSS: 2018. Grupos Relacionados con el Diagnóstico: Producto hospitalario. Direccion de Prestaciones Medicas; 2018.
   Google Scholar
• IMSS. ACUERDO ACDO. AS3.HCT.271119/329.P.DF; 2019.
   Google Scholar
• Instituto Mexicano del Seguro Social. ACUERDO ACDO. AS3.HCT.271119/329.P.DF; 2019.
   Google Scholar
• Instituto Mexicano del Seguro Social. GRD – IMSS: 2018. Grupos Relacionados con el Diagnóstico: Producto hospitalario. Direccion de Prestaciones Medicas; 2018.
   Google Scholar
• Body JJ, Pereira J, Sleeboom H, et al. Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ. 2016;17(6):711–721.
   PubMed Web of Science ®Google Scholar
• Diel I, Ansorge S, Hohmann D, et al. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. Support Care Cancer. 2020;28(11):5223–5233.
   PubMed Web of Science ®Google Scholar
• Alibhai SMH, Zukotynski K, Walker-Dilks C, et al. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care – cancer care Ontario clinical practice guideline. Clin Oncol. 2017;29(6):348–355.
   Web of Science ®Google Scholar
• Haynes I, Woll PJ, Flinois A, et al. Insights into the management of bone metastases in patients with lung cancer: a comprehensive European survey. Poster presented at: European Cancer Congress 2013 (ECCO-ESMO-ESTRO); 2013 Sep 27-Oct 1; Amsterdam, The Netherlands.
   Google Scholar
• Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):425–437.
   PubMed Web of Science ®Google Scholar
• Liauw W, Segelov E, Lih A, et al. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer. 2005;5:89.
   PubMed Web of Science ®Google Scholar
• Body JJ, Acklin YP, Gunther O, et al. Pathologic fracture and healthcare resource utilisation: a retrospective study in eight European countries. J Bone Oncol. 2016;5(4):185–193.
   PubMed Web of Science ®Google Scholar
• von Moos R, Body JJ, Guenther O, et al. Healthcare-resource utilization associated with radiation to bone across eight European countries: results from a retrospective study. J Bone Oncol. 2018;10:49–56.
   PubMed Web of Science ®Google Scholar
• Peters DH, Garg A, Bloom G, et al. Poverty and access to health care in developing countries. Ann N Y Acad Sci. 2008;1136:161–171.
   PubMed Web of Science ®Google Scholar